Artikel
MACC1 – the first prognostic plasma biomarker for glioblastoma multiforme?
Suche in Medline nach
Autoren
-
Carsten Hagemann
- Universität Würzburg, Neurochirurgische Klinik und Poliklinik, Tumorbiologisches Labor, Würzburg, Germany
-
Nikolas Neuhaus
- Universität Würzburg, Neurochirurgische Klinik und Poliklinik, Tumorbiologisches Labor, Würzburg, Germany
-
Almuth F. Kessler
- Universität Würzburg, Neurochirurgische Klinik und Poliklinik, Tumorbiologisches Labor, Würzburg, Germany
-
Pia Herrmann
- Experimental and Clinical Research Center, Charité University Medicine Berlin, at the Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
-
Matthias Eyrich
- Universität Würzburg, Kinderklinik und Poliklinik, Abteilung für Hämatologie/Onkologie, Würzburg, Germany
-
Ulrike Stein
- Experimental and Clinical Research Center, Charité University Medicine Berlin, at the Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| Veröffentlicht: | 8. Juni 2016 |
|---|
Gliederung
Text
Objective: Metastasis-associated in colon cancer-1 (MACC1) is an independent prognostic indicator of metastasis formation and metastasis-free survival for patients suffering from colon cancer. In these cases MACC1-plasma levels have been established for a prognostic prediction. Recently, we presented data indicating that MACC1 expression levels in glioma tissue were associated with the WHO grading of gliomas on mRNA- and protein-level. We also showed that MACC1 overexpression promoted proliferation, migration, invasion and tumor formation of glioblastoma multiforme (GBM) cells, most likely involving the HGF-Met signaling-pathway. Here we determined, whether the concentration of MACC1 mRNA detectable in the plasma of GBM-patients could serve as a prognostic biomarker.
Method: Blood-plasma samples were collected from 36 GBM patients before surgery and from 15 healthy volunteers as controls. MACC1-transcripts were detected by quantitative PCR in the samples and their expression correlated with survival and clinical data of prognostic significance as sex, age, Karnofsky index/ECOG score, tumor volume, degree of resection, MGMT-promoter methylation status and the Ki67-proliferation index. In addition, tumor tissue samples of these patients were stained for MACC1 expression by immunohistochemistry.
Results: In addition to the previously published MACC1 overexpression in GBM that was confirmed by immunohistochemical staining in the current study, MACC1 transcripts could also be detected in the plasma of those patients. Transcript levels were significantly increased in comparison to the healthy controls. The median expression of MACC1 was 0.3072. Patients with lower (n = 18) or higher (n = 18) MACC1 expression were accordingly distributed to two groups and their survival compared. The MACC1 plasma concentrations were negatively correlated with the patients' prognosis. Of the other clinical data only the age of the patients was significantly different in the two groups.
Conclusions: Although our study is limited by the small sample size, we describe the first detection of MACC1 in plasma samples of GBM patients. Our data show that MACC1 might serve as the first blood biomarker of prognostic significance in GBM.
